- During the given period, Noxopharm’s (ASX:NOX) prime focus was on bringing Veyonda® towards achieving marketing approval, post observing impressive results in the DARRT-1 Phase 1b Study with 48% of men with Stage 4 prostate-cancer showing durable anti-cancer response at 6 months.
- Given the encouraging positive outcomes of DARRT-1, the company is proceeding to multi-national placebo-controlled DARRT phase 2 clinical trial.
- Noxopharm is expecting to release its well progressing LuPIN trial’s all-important overall survival data on the first 32 men by mid of February 2020.
- Veyonda® is on its way to become groundbreaking immunotherapy for late-stage cancers.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.